Houston — much like the rest of the world — has a growing freelance economy. A local innovator has created a platform for freelancers to find work. Photo courtesy of Common Desk

By 2027, freelancers will account for the majority of the American workforce — and Houston is already well represented by the freelance space.

According to a recent study, Houston is home to 117,260 skilled freelancers who generated more than $4.1 billion in revenue in 2018. This burgeoning environment for freelancers presents many opportunities for innovations in the tech world, as one Houston entrepreneur has already discovered.

Yared Akalou, founder-and-CEO of Alcove Group and self-described designer-focused entrepreneur, released his third innovation catering to freelancers of the Houston area. His digital solutions platform, IAmOther50, assists freelancers with securing new clients by sharing their personal stories rather than just submitting their professional experience, it uses videos and articles to promote the work of a freelancer and connect them to their next client.

"I am really on a mission," Akalou tells InnovationMap. "I have been talking about the future of work for over a decade now. The paradigm will change to viewing work as a service, so it is important to tell a freelancer's story through a more engaging and novel way."

At first glance, the digital platform seems like a departure for Akalou who in 2017 founded Alcove, a portable laptop case that serves as a private workspace for freelancers to use amid coffee shops or coworking spaces. However, IAmOther50 serves as a distinctly separate yet integral part of his innovation landscape.

"These projects have been a combination of my focus and research," says Akalou. "My new platform works hand in hand with Alcove, supporting the mission to help people stay productive from anywhere."

The digital platform serves to capture the brand of the freelancer along with their personality and experience. It lives at the intersection of popular social media platforms and professional platforms such as LinkedIn, except just for freelancers in the Houston area. Currently, any freelancing professional in the Houston area can join for free by filling out a survey that customizes their goals for their profile.

"IAmOther50 provides information in a contextual way," says Akalou. "We have this guiding principle of delivering value even before the prospective client contacts the freelancer for an interview or potential position. It's about going beyond just a resume of what you've done and showcasing how you add value right now."

Akalou, who is also one of the mentors in The Ion Smart and Resilient Cities Accelerator, is focused on elevating the professional profiles of many freelancers, including those outside the Houston area. He is aiming to grow the platform to a self-service platform that can connect freelancers to clients all over the biggest metropolitan areas soon.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”